TickerFacts.

Compare

CytomX Therapeutics, Inc. vs AbCellera Biologics Inc. vs Eton Pharmaceuticals, Inc. vs Bicycle Therapeutics PLC

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCytomX Therapeutics, Inc.
CTMX		AbCellera Biologics Inc.
ABCL		Eton Pharmaceuticals, Inc.
ETON		Bicycle Therapeutics PLC
BCYC
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$76.20M$75.13M$79.95M$72.59M
Revenue growth (YoY)-44.8%+160.6%+104.9%+105.8%
Gross marginn/an/a53.5%n/a
Operating margin-29.3%-289.0%-1.1%-340.4%
Net margin-22.8%-194.9%-5.8%-301.7%
Net income-$17.37M-$146.41M-$4.60M-$218.96M
EPS (Diluted)n/a-$0.49n/a-$3.16
Operating cash flow-$75.59M-$131.29M$10.52M-$249.68M
Free cash flow-$75.81M-$174.07M$10.19M-$252.03M
Cash & equivalents$12.67M$128.51M$25.94M$628.11M
Total assets$151.57M$1.36B$92.11M$717.60M
Total liabilities$52.56M$390.05M$65.96M$107.62M
Shareholders' equity$99.01M$966.90M$26.15M$609.98M
Return on year-end equity-17.5%-15.1%-17.6%-35.9%
Shares outstanding170.19M300.60M27.05M69.37M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCytomX Therapeutics, Inc.AbCellera Biologics Inc.Eton Pharmaceuticals, Inc.Bicycle Therapeutics PLC
Latest$76.20M
Ended 2025-12-31		$75.13M
Ended 2025-12-31		$79.95M
Ended 2025-12-31		$72.59M
Ended 2025-12-31
1 year earlier$138.10M
Ended 2024-12-31		$28.83M
Ended 2024-12-31		$39.01M
Ended 2024-12-31		$35.27M
Ended 2024-12-31
2 years earlier$101.21M
Ended 2023-12-31		$38.02M
Ended 2023-12-31		$31.64M
Ended 2023-12-31		$26.98M
Ended 2023-12-31
3 years earlier$53.16M
Ended 2022-12-31		$485.42M
Ended 2022-12-31		$21.25M
Ended 2022-12-31		$14.46M
Ended 2022-12-31
4 years earlier$37.31M
Ended 2021-12-31		$375.20M
Ended 2021-12-31		$21.83M
Ended 2021-12-31		$11.70M
Ended 2021-12-31